Skip to main content
OpenTrials
Completed

NCT Number: NCT04752709

Efficacy of Surface Electrical Stimulation for Urge Urinary Incontinence in Women

The purpose of this research is to evaluate the effectiveness of the ELITONE-UUI electrical muscle stimulation device on treating urge incontinence. The aim of the device is to stimulate the pelvic floor muscles and surrounding structures to improve urinary incontinence.

Completed

Looking for future studies?

Notify Me

Key information

About this study

The purpose of this research is to evaluate the effectiveness of the ELITONE-UUI electrical muscle stimulation device on treating urge incontinence in women. The aim of the device is to stimulate the pelvic floor muscles and surrounding structures to improve urinary incontinence. This is a randomized prospective controlled study of two active groups with a stimulation frequency difference between the groups.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Predominant urge urinary incontinence as determined by responses to a series of three standard questions from the King's Health Questionnaire; specifically:
  • An affirmative response to "Is it very difficult to control when you have a strong urge to urinate?",
  • An affirmative or negative response to "Do you lose urine with physical activities such as coughing, sneezing, running?",
  • And, if an affirmative response to the second question, an affirmative response to "Are more of your incontinence episodes due to a strong urge to urinate than to abdominal pressure such as sneezing?"
  • Mild-moderate incontinence symptoms as determined by self-reported typical number of accidents of 1 or more per 24 hours. Symptom severity is later verified with data from the Daily Log (See 5.4)

Exclusion criteria

  • Less than 1 incontinence accident (leak) per day*
  • Severe incontinence as determined by self-reported >5 accidents per day
  • Currently pregnant, may be pregnant, attempting to become pregnant, or delivery within previous 6 weeks
  • Vaginal or pelvic surgery within previous 6 months
  • Severe Obesity as defined by BMI >= 35
  • Change in incontinence medication type or dosing within the last 3 months.
  • History or symptoms of urinary retention, extra-urethral incontinence, overflow incontinence
  • Pelvic pain/painful bladder syndrome
  • Active urinary tract infection (UTI) or history of recurrent UTIs (more than three in a year), or recurrent vaginitis (bacterial/fungal)
  • Tissues protruding outside the vagina at rest
  • Presence of incontinence-associated dermatitis or other perineal skin disorders or lesions,
  • Complete denervation of the pelvic floor
  • Conductive inter-uterine devise (IUD/Coil) or metal implants in the abdominal or pelvic area, including the hip and lumbar spine,
  • Chronic coughing
  • Previous use of Interstim device or Botox for UI
  • Implanted cardiac device, untreated cardiac arrhythmia or suffer from other heart problems.
  • Cancer, epilepsy or cognitive dysfunction
  • Underlying neurologic/neuromuscular disorder
  • Impaired decision making, suicidal thoughts, or drug/alcohol dependence
  • Lacks capacity to consent for themselves.

Treatment and study plan

ELITONE UUI

Device

External electrical stimulation

Other names: ELITONE muscle stimulator

Primary outcomes

  1. Change in Average Number of Urinary Incontinence Episodes Per Day

    Time frame: 6 weeks

    The efficacy of a treatment for urinary incontinence measures how much the treatment changed urinary incontinence leakage from the beginning to the end of the 6 week period.

  2. Safety Assessed by Number of Serious Adverse Events

    Time frame: 6 weeks

    Any serious adverse events recorded during the trial.

Secondary outcomes

  1. Efficacy Assessed by Change in Incontinence Quality of Life Questionnaire (I-QOL)

    Time frame: 6 weeks

    The efficacy assessed by change in Incontinence quality of life questionnaire (I-QOL). The scale is as follows: 1 = not at all , 2 = a little, 3 = moderately, 4 = quite a bit and 5 = extremely. The lower the value the less times it happens and the better outcome. A larger results indicate a higher change in I-QOL from beginning to end of trial. The minimum score total is 22 and maximum total score is 110.

  2. Efficacy Assessed by Reduction in Average Pads Used Per Day

    Time frame: 6 weeks

    Efficacy Assessed by Reduction in Average Pads used per day over the 6 week period.

  3. Efficacy Assessed by Reduction in Average Bathroom Visits

    Time frame: 6 weeks

    The efficacy assessed by average bathroom visits during the day and night.

Sponsors and collaborators

Lead sponsor

Elidah, Inc.

Industry

Registry information

Official study title

Clinical Study to Evaluate the Efficacy of Surface Electrical Stimulation for Urge Urinary Incontinence in Women

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Feb 12, 2021
Registry last updated
Dec 30, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.